• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 18 Suven Life Sciences Ltd commenced Phase I clinical trials of its drug candidate for treatment of Alzheimer’s disease and other memory disorders at Basle, Switzerland.

The drug (SUVN – 502) is the lead compound selected from over 500 compounds designed and developed through a combination of traditional and rational medicinal chemistry approaches.

The study, to be completed by December, is being conducted using single and multiple oral doses with the objective of assessing safety and bioavailability of the drug in 67 healthy human beings.

More Stories on : Research & Development | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
KSDP being modernised

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line